Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 1Q Financial Report: Wyeth | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

1Q Financial Report: Wyeth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth

1Q Revenues: $4.8 billion (+6%)

1Q Earnings: $1.1 billion (+13%)

Comments: Enbrel, Effexor, Prevnar, Premarin and Protonix drove revenue growth in the quarter. The company has rights to Enbrel outside of the U.S. and Canada where net revenue was $335 million for the quarter, up 42%. Effexor sales were $945 million, up 9%. Prevnar sales were up 10% to $432 million. Premarin product sales were $266 million for the quarter, up 26%. Protonix sales were $482 million, up 18%. R&D expenses were $684.7 million for the quarter, up +13%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters